Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02706626
Title Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Criterium, Inc.
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST